Drug intelligence / Profile preview

EMP405

Development stage: Preclinical
Lead developer: Empiriko
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMP405 is a preclinical-stage somatostatin receptor (SSTR)-targeted radioligand therapy being developed by Empiriko for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug utilizes Empiriko's proprietary RCV (azamacrocycle carrier) platform to deliver the lutetium-177 (177Lu) radioisotope to tumor cells expressing SSTR. Its unique mechanism of action involves the RCV carrier functioning as a co-drug that amplifies therapeutic efficacy by generating oxidative damage via singlet oxygen radicals, complementing the beta radiation emitted by the 177Lu isotope. This dual-action approach is designed to enhance the anti-tumor effect compared to traditional radioligand therapies.

Targets

SSTR2 (Somatostatin receptor type 2)SSTR (Somatostatin receptors)

Beyond the preview

Go deeper on EMP405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP405.